GOT1 and stroke disorder: We and our colleagues previously reported a neuroprotective effect of reducing blood glutamate levels by the administration of recombinant GOT1 and oxaloacetate in SAH, spinal cord injury, stroke, and Paraoxon intoxication animal models22–25.